The laboratory of Immunobiology of Dendritic Cells applies a bedside-to-bench approach to scientific discovery that ensures our team stays rooted in medically relevant questions, while striving to make new fundamental discoveries about immunity to disease.
Our laboratory is a mixed INSERM / Pasteur Unit. Our original founding scientific objective was to characterize immune responses initiated by dying cells. The commitment to this field of study stems from our discovery that dead cells serve as a source of antigen for dendritic cell cross-presentation and cross-priming. As the group has evolved, we have tackled this from multiple perspectives with the findings leading to new projects in unexpected directions. Our principle scientific aims are:
- Defining how variable cell death programs influence inflammation and immunity
- Understanding how immunity is initiated from the bladder mucosa in the context of infection and cancer immunotherapy
- Exploring the mechanisms that limit inflammation and control the trafficking of effector immune cells
In addition to these scientific research goals, we are transfering our insights into biomarkers for treatment response and drug targets for improving treatment outcome, back into the clinic completing the circle “bench-to-bedside”. For these clinical studies, we have been focusing on viral hepatitis and cancer.
Our laboratory has played a leading role in the establishment of the Milieu Intérieur Project. We contributed our expertise to the development and use of whole blood syringe-based assay systems (TruCulture) that can be used to reproducibly assess induced innate or adaptive immune responses. Early results from the Consortium’s work have provided an initial assessment of healthy donor reference values for microbe-induced cytokines and chemokines. Our laboratory is now focusing on the deconvolution of the healthy immune response, and applying these approaches for a better understanding of perturbed immune responses in viral hepatitis and tuberculosis.